COVID-19 Candidates Information Updated: 05/11/2021

Manufacturer Doses Handling + Efficacy Timeline of Fed Govt Technology/Type Requirements Administration Development Contract Pfizer/BioNTech mRNA vaccine Distributed at - Original Mix with Reported 95% EUA granted Dec. 120 million 80 to -60 ᵒC and for 5 diluent on site. efficacy (Press 11, 2020. total by the 2 dose series 21 can be stored at doses/vial in Release) end of March days apart this temperature protocol. Once one vial 2021 and until expiry date. Changed to 6 removed from Efficacy reduced began Dec. 14, another 180 doses per vial. pizza box, the towards UK and 2020 million by the May be stored entire box is South African end of July. -25ᵒC to -15ᵒC FDA advises considered as Variants (Press Phase I clinical for two weeks to use all having started Release). trial to investigate Allocations for cumulatively available to thaw. the safety and Pfizer doses with one return doses, now Reported 100% efficacy of a 3rd will likely see to -80 to -60 ᵒC. considered 6 May be efficacy in booster shot of a small (may be able transported at adolescents 12- Pfizer COVID-19 decrease as Stable for 5 to get 7). -25ᵒC to - 15 years of age vaccine began Pfizer hours: 2-8 ᵒC 15ᵒC. (Press Release). February 25, 2021 completes Minimum (here). their first 200 Stable for up to order: 1024 million dose 30 days in doses (based Recruiting contract 2-3 shipping box if on 5 doses per pregnant women weeks ahead dry ice is vial) for a Phase II/III of the May maintained and trial (here). 31st deadline. 5 days after at 2- Allocations 8 ᵒC for a total of In March, the first will go back up 35 days. children of the as Pfizer Phase1/2/3 study transitions were given doses into their next of vaccine (here). 100 million dose March 31, 2021, manufacturing Phase III trial in contract. the US among 2

adolescents 12-15 years of age was completed and results were released (here).

April 9, 2021 Pfizer requests EUA for adolescents ages 12-15 (Press Release).

May 7, 2021 Pfzifer applied for full licensure of vaccine (here).

Moderna mRNA vaccine Lasts for 6 10 doses/vial No dilution or Reported 94.1% EUA granted Dec. Total 300 months at -25ᵒC special efficacy (Press 18, 2020. million doses 2 dose series 28 to -15ᵒC Minimum handling on Release) by July spread days apart order is 10 site. Vaccination out as: 100 Can be stored vials: 100 Efficacy reduced began Dec. million by the for 30 days 2-8 doses towards UK and 21,2020. end of March ᵒC prior to first South African 2021, 100 use Variants (Press March 10, 2021 million by the Release). began trial to end of May, Good for 12 evaluate a and another hours at 8-25ᵒC COVID-19 100 million by vaccine booster the end of July Vaccine is viable for the South 2021. for 6 hours once African variant vial is pierced (here). (Press Release) March 15, 2021 began Phase I trial for next

2

generation COVID-19 vaccine mRNA- 1283 (here).

March 16, 2021 first patients doses in Phase II/III enrolling children aged 6 months to 12 years (here). Janssen (+ 1 dose Storage at 2-8 5 dose/vial of No Reported 66% EUA granted 20 million by Johnson & Adenovirus ᵒC for up to 0.5mL dose preservative in efficacy globally February 27, the end of Johnson) Vector based three months vial, no and 74% within 2021. March, vaccine 10 vials per reconstitution the US. another 100 After first use carton, 48 required at Preliminary data Vaccination million by the lasts for 6 hours cartons per site. suggest JnJ began March 1, end of July at 2-8 ᵒC shipper = vaccine may be 2021. 2400 doses Do not effective in Expected to per shipper vigorously preventing April 13, 2021, remain stable shake, but SARS-CoV-2 CDC and FDA for up to two Minimum otherwise can (here). recommended a years at -20° C. order 100 handle driving pause in J&J doses. on bumpy (here). roads or being jostled. April 23, 2021, ACIP voted to resume use of JnJ vaccine in adults 18 years and older in the US (ACIP Recommendation) after reviewing a total of 15 cases of thrombosis- thrombocytopenia syndrome (TTS)

2

that had been reported in VAERS. All cases were found in women ages 18- 59 and symptom onset was 6-15 days after vaccination. The CDC and FDA continue to monitor the safety of COVID-19 . AstraZeneca and Adenovirus Storage at 2-8 No dilution or 90% reported A phase III trial in 300 mil doses Oxford Vector based, 2 ᵒC for 6 months reconstitution for the group the US of 30,000 doses who received a participants is After first half dose and expected to yield puncture, store then a full dose. clarifying results up to 6 hours at on the best dose room 60% reported regimen. temperature or for the group up to 48 hours at who received 2 Approved in UK, 2-8 ᵒC full doses (read Argentina, Brazil, more here) India, and COVAX. Use suspended in Feb 2, 2021: Germany, France, reported single Italy, Norway, dose 76% Denmark, Iceland, efficacy and Netherlands. after second dose given 12 April 7, 2021, the weeks later was European 82.4%. Data also Medicines Agency suggests (EMA) lists blood reduced clotting as transmission in potential side addition to effect of

2

prevention of AstraZeneca’s symptoms (here) COVID-19 vaccine (Press Release). NOVAVAX Protein-based Storage at 2-8 10 doses/vial Co-formulated Final analysis of Phase III trial in 110 million vaccine candidate ᵒC with adjuvant. UK trial US began Dec. 28, purchased by containing Handling at Minimum No mixing confirms 96.4% 2020 with goal of the US derived room temp: 25 order: assume required. efficacy against enrolling 30,000 from the ᵒC 100 doses original COVID- participants spike Very stable 19 and 86.3% (here). (S) protein. under stress against B.117 conditions, will (UK) strain. Rolling Review 2 dose series utilize standard Complete with FDA going on analysis from now. Phase 2b trial in South Africa Novavax is reports 55.4% hopeful to apply efficacy against for EUA in May B1.351 strain. using UK data, Across both otherwise EUA trials 100% application will protection occur summer against severe 2021 when the US , Phase III trial hospitalization, ends. and death (here).

MEDICAGO Plant produced Stable at 4-8 ᵒC 10 doses/vial 1 dose of Phase III trial Coronavirus-Like product + 1 began March 16, Particle COVID- Minimum dose of 2021 (here). 19 vaccine order: assume adjuvant candidate 100 doses Mixed on site (CoVLP) is composed of recombinant spike (S) glycoprotein

2

expressed as -like particles (VLPs).

2 dose series 21 days apart INOVIO INO-4800 DNA Stable at 25 ᵒC 10 doses/vial CELLECTRA Phase 1 data vaccine (2-dose for >1 year, hand-held published on June series) 37 ᵒC for >2 Minimum smart device 30, 2020. months order: assume uses electrical In buffer, 2-8 ᵒC 100 doses pulse to deliver In early May, for >5 years vaccine Phase II showed tolerable results, FDA approval seeking FDA of CELLECTRA approval for device Phase III (here). continues to delay start of PhaseII/III clinical trial Sanofi Pasteur + recombinant Storage 2-8 ᵒC 10 doses of Recombinant Began Phase I/II 100 mil doses GlaxoSmithKline protein for product and product/vial vaccine on Sept. 3, 2020. adjuvanted adjuvant 10 doses product + + optional vaccine (2 dose adjuvant/vial adjuvant Disappointing purchase of series) Administration: phase I/II results, 500 mil doses 25 ᵒC Minimum Mixed on site. Phase 2b trial order: assume with modified 100 doses vaccine product began February 22, 2021 (here). Sanofi Pasteur + mRNA vaccine Storage at -20 Minimum Phase I/II trial TranslateBio MRT5500 ᵒC order: assume initiated March 100 doses 12, 2021 (here). 1 or 2-dose series, 21 days apart being evaluated

2

MERCK + IAVI DISCONTINUED (V590) MERCK #2 DISCONTINUED (V591)

Sources: • https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html • https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html • https://www.reuters.com/article/health-coronavirus-astrazeneca-vaccine/u-s-astrazeneca-vaccine-trial-will-clear-confusion-on-how-well-it- works-u-s-scientist-idUSKBN28H1YL • http://s23.q4cdn.com/479936946/files/doc_news/INOVIO-and-Advaccine-Announce-First-Dosing-of-Subject-in-Phase-2-Clinical-Trial-for- COVID-19-DNA-Vaccine-Candidate-INO-4800-in-China-2020.pdf • https://www.medicago.com/en/newsroom/medicago-and-gsk-announce-start-of-phase-2-3-clinical-trials-of-adjuvanted-covid-19-vaccine- candidate/ • https://www.sanofi.com/en/about-us/our-stories/sanofi-s-response-in-the-fight-against-covid-19 • https://www.ox.ac.uk/news/2021-02-02-oxford-coronavirus-vaccine-shows-sustained-protection-76-during-3-month-interval • https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/02-COVID-Villafana.pdf • https://www.reuters.com/article/us-health-coronavirus-inovio-pharma/inovio-expects-to-begin-late-stage-covid-19-vaccine-study-in-second- quarter-idUSKBN2991HR • https://www.nytimes.com/2021/02/12/health/covid-vaccines-children.html • https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine • https://www.reuters.com/article/us-novavax-results/novavax-covid-19-shot-could-be-cleared-for-u-s-use-by-may-ceo-idUSKCN2AT3MD • https://www.reuters.com/article/us-health-coronavirus-astrazeneca-usa/exclusive-u-s-green-light-for-astrazeneca-vaccine-could-come-in- april-independent-monitors-assessing-data-us-official-idUSKBN2B723D • https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal • https://cdn.pfizer.com/pfizercom/2021-04/EUA-12-15yo-Statement-9-April-2021.pdf • https://www.pfizer.com/news/hot-topics/why_pfizer_opposes_the_trips_intellectual_property_waiver_for_covid_19_vaccines • https://www.janssen.com/us/sites/www_janssen_com_usa/files/johnson-johnson-statement-on-covid-19-vaccine.pdf • https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine • https://www.janssen.com/us/sites/www_janssen_com_usa/files/johnson-and-johnson-statement-on-april-23-cdc-advisory-committee- meeting-on-company-covid-19-vaccine.pdf • https://www.janssen.com/us/sites/www_janssen_com_usa/files/johnson_johnson_single-shot_covid- 19_vaccinations_to_resume_in_the_us_for_all_adults_aged_18_and_older_following_cdc_and_fda_decision.pdf • https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine- use-following-thorough

2

• https://www.astrazeneca.com/media-centre/articles/2021/update-following-mhra-and-ema-decisions-on-astrazenecas-covid-19- vaccine.html • https://www.medrxiv.org/content/10.1101/2021.05.07.21256652v1

2